CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
736-750 of 1225
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
CME/CEFAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
CardiologyKidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John W. Ostrominski, MD, MPH
The Alloimmune Disorders of Pregnancy: Optimizing Fetal Outcomes Through Advances in Diagnosis and Treatment
CME/CEThe Alloimmune Disorders of Pregnancy: Optimizing Fetal Outcomes Through Advances in Diagnosis and Treatment
William Goodnight, MD, MSCR
Kara B. Markham, MD
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Harry Yoon, MD
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
MinuteCE®Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Jenny Seligmann, MBChB, PhD
Fortunato Ciardiello, MD, PhD
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
- advertisement
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
MinuteCE®Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Patient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
CME/CE Broadcast ReplayPatient-Centric ADT Intensification in Hormone-Sensitive Prostate Cancer: Balancing Efficacy, Safety, Quality of Life, and Survival
Mary-Ellen Taplin, MD
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Jaffer Ajani, MD
- advertisement
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD